Validation of a novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study

Alanine aminotransferase (ALT) measurement is essential for evaluation of liver disease. We validated a novel rapid point‐of‐care (POC) test for ALT1 against laboratory ALT.

[1]  C. Treloar,et al.  "That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison. , 2021, The International journal on drug policy.

[2]  V. Sundararajan,et al.  Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis , 2021, Gut.

[3]  H. Razavi.  The cost‐effectiveness of hepatitis C virus elimination in low‐ and middle‐income countries , 2020, Journal of viral hepatitis.

[4]  E. Tapper,et al.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  J. Lazarus,et al.  A global investment framework for the elimination of hepatitis B , 2020, Journal of Hepatology.

[6]  M. Hellard,et al.  Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age. , 2020, Journal of hepatology.

[7]  I. Waked,et al.  Screening and Treatment Program to Eliminate Hepatitis C in Egypt. , 2020, The New England journal of medicine.

[8]  T. H. Nguyen,et al.  The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The lancet. Gastroenterology & hepatology.

[9]  M. Hellard,et al.  Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study. , 2019, The International journal on drug policy.

[10]  Lisa Aufegger,et al.  Innovative strategies for the elimination of viral hepatitis at a national level: A country case series , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[11]  N. Berhe,et al.  A novel score to select patients for treatment in chronic hepatitis B: Results from a large Ethiopian cohort. , 2019, Journal of hepatology.

[12]  T. Weiland,et al.  Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. , 2019, The International journal on drug policy.

[13]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[14]  M. Thursz,et al.  Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe. , 2019, Journal of hepatology.

[15]  R. Peeling,et al.  Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. , 2019, The lancet. Gastroenterology & hepatology.

[16]  G. Dore,et al.  Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. , 2018, The International journal on drug policy.

[17]  U. d’Alessandro,et al.  Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. , 2018, Journal of hepatology.

[18]  P. Gow,et al.  Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C. , 2018, Journal of hepatology.

[19]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[20]  R. Peeling,et al.  The future of viral hepatitis testing: innovations in testing technologies and approaches , 2017, BMC Infectious Diseases.

[21]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[22]  A. Bungert,et al.  Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey amongst Mongolian adults , 2017, Journal of viral hepatitis.

[23]  H. Whittle,et al.  Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. , 2016, The Lancet. Global health.

[24]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[25]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[26]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[27]  R. Kim,et al.  Isoform-specific alanine aminotransferase measurement can distinguish hepatic from extrahepatic injury in humans. , 2012, International journal of molecular medicine.

[28]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[29]  S. P. Akpabio.  World Health Organisation , 1983, British Dental Journal.